Philadelphia Biotech Company Secures $1 Million State Grant for Pandemic Research Center Expansion
By Chris Frew
June 27, 2023
| BioBuzz has been connecting the life science workforce since 2009. We’ve built an expansive community in the Mid-Atlantic with a national readership that spans from Massachusettes to Florida, and New York to California. For our next chapter, we’re building a proprietary talent logistics model to help employers source and hire life science talent. Learn more. |
Philadelphia-based biotechnology company, Integral Molecular, has received a significant boost in funding from the Commonwealth of Pennsylvania. The company has been awarded $1 million through the Redevelopment Assistance Capital Program (RACP) to support the expansion of its headquarters and the development of its Pandemic Research Center. This investment will facilitate the construction of an additional 16,000 square feet of office space and state-of-the-art laboratory facilities, reinforcing Integral Molecular’s commitment to advancing research reagents for studying emerging viruses.
Integral Molecular recently celebrated the inauguration of its new headquarters at One uCity Square in Philadelphia. With this latest expansion, the company aims to double its present workforce in the region, generating a total of 200 technology jobs. The enhanced facility will not only enable Integral Molecular to bolster its research and development efforts but also contribute significantly to Pennsylvania’s biotechnology sector.
Having garnered over two decades of expertise in studying viruses, Integral Molecular has played a pivotal role in Pennsylvania’s response to the COVID-19 crisis. The company has been at the forefront of biotechnological innovation, developing over 75 variants of safe SARS-CoV-2 “pseudovirus” for researchers seeking alternatives to working with live and potentially dangerous viruses. These research tools have been instrumental in laboratories worldwide for the development of vaccines and antiviral therapeutics. Integral Molecular has also expanded its virology offerings to include safe laboratory testing options for influenza, Ebola, Marburg, dengue, and Zika pseudovirus reporter particles.
Vincent Hughes, State Senator of Pennsylvania, commended Integral Molecular’s contribution to scientific discoveries in Philadelphia. He expressed pride in the region’s reputation as “Cellicon Valley,” where transformative technologies like RNA immunization and cell and gene therapy were born. Senator Hughes acknowledged the importance of supporting Integral Molecular in its mission of pandemic preparedness and recognized the positive impact of the company’s expansion on job creation in the area. The $1 million grant received by Integral Molecular forms part of the nearly $29 million in RACP funding announced by Senator Hughes’ office.
Integral Molecular, with its extensive experience in developing innovative technologies, is a leader in the field of discovering therapeutics for challenging protein targets. Over the past 20 years, the company’s expertise in membrane proteins and antibodies has been integrated into the drug discovery pipelines of more than 500 biotech and pharmaceutical companies. This collaborative approach has contributed to the development of new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
